ENVISIA
LIVE

Serial Number

97815166

Owner

Veracyte, Inc.

Attorney

ROSALEEN H. CHOU

First Use Date

May 17, 2018

Filing Date

Feb 28, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ENVISIA Trademark

Serial Number: 97815166 • Registration: 8098213

ENVISIA is a trademark filed by Veracyte, Inc. on February 28, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Veracyte, Inc. (31 trademarks)

7000 Shoreline Court
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

February 28, 2023

Registration Date

January 13, 2026

First Use Anywhere

May 17, 2018

First Use in Commerce

May 17, 2018

Published for Opposition

November 25, 2025

Goods & Services

Reagents for scientific or research use; Diagnostic kits and test kits primarily composed of reagents for determination of genomic and transcriptomic information for scientific or research purposes; Testing kits comprised primarily of preparations, reagents, test strips, collection tubes, buffers, tube holders, transport bags and assays for use in scientific or research in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Biological agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for scientific and research use; Diagnostic reagents and preparations, other than for medical and veterinary use; Kits comprised primarily of biological reagents and comprised secondarily of a protocol in the form of printed instructions for use thereof for scientific and research purposes; Tests designed to isolate and extract cells for genetic analysis comprised of reagents for scientific or research purposes; Reagents and molecule or cell markers for scientific or research purposes

Kits for in vitro diagnostic testing for pulmonary diseases and conditions; Reagents for medical use; Molecular diagnostic assays for testing of bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Medical preparations used to diagnose bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Diagnostic agents, preparations and substances for medical purposes; Diagnostic test kits consisting primarily of reagents for use in testing bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Medical diagnostic test kits consisting primarily of reagents for detecting pathogens; Clinical medical diagnostic reagents, medical diagnostic assays for medical and diagnostic purposes for testing genetic material; Clinical, genetic and specialized medical diagnostic test kits comprised primarily of buffers, collection tubes, tube holders, transport bags, shipping containers, and instruction sheets for use in scientific and clinical diagnostic equipment used to detect disease, cancer, genetics, and pathogens; Chemicals, assays, reagents and kits consisting primarily of chemicals, assays, and reagents for medical testing and diagnostic purposes in the fields of genomics, diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Medical diagnostic reagents, and kits comprised of medical diagnostic reagents, collection tubes, buffers, tube holders, transport bags, and instruction sheets, for diagnostic testing in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Medical diagnostic testing kits comprised primarily of reagents and assays for use in diagnostics and diagnostic testing in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Tests designed to isolate and extract cells for genetic analysis comprised of reagents for medical diagnostic use

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 13, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 13, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 28, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 27, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 27, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Oct 27, 2025 ERSI
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jun 25, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Dec 27, 2024 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 28, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 28, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jun 28, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 29, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 29, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 29, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 22, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 22, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 29, 2023 GNRN
NON-FINAL ACTION E-MAILED
Nov 29, 2023 GNRT
NON-FINAL ACTION WRITTEN
Nov 29, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 29, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 19, 2023 NWOS
NEW APPLICATION ENTERED
Mar 3, 2023 NWAP